Search hospitals > Wisconsin > Madison
Veterans Affairs Medical Center - Madison
Claim this profileMadison, Wisconsin 53705
Global Leader in Prostate Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Colorectal Cancer
Conducts research for Non-Small Cell Lung Cancer
115 reported clinical trials
10 medical researchers
Summary
Veterans Affairs Medical Center - Madison is a medical facility located in Madison, Wisconsin. This center is recognized for care of Prostate Cancer, Lung Cancer, Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer and other specialties. Veterans Affairs Medical Center - Madison is involved with conducting 115 clinical trials across 162 conditions. There are 10 research doctors associated with this hospital, such as Justine Yang-Bruce, Nasia Safdar, MD PhD, Christopher D Fletcher, MD, and Jessica M. Schuster.Area of expertise
1Prostate Cancer
Global LeaderStage IV
CDK12 positive
CHEK2 positive
2Lung Cancer
Global LeaderStage II
Stage I
Stage III
Top PIs
Justine Yang-BruceWilliam S Middleton VA Medical Center9 years of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
6 reported clinical trials
13 drugs studied
Nasia Safdar, MD PhDWilliam S. Middleton Memorial Veterans Hospital, Madison, WI2 years of reported clinical research
Studies Clostridium Infections
Studies Clostridium Difficile
4 reported clinical trials
6 drugs studied
Christopher D Fletcher, MDUniversity of Wisconsin Carbone Cancer Center5 years of reported clinical research
Studies Lymphoma
Studies Diffuse Large B-Cell Lymphoma
4 reported clinical trials
13 drugs studied
Jessica M. SchusterWilliam S Middleton VA Medical Center2 years of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
3 reported clinical trials
6 drugs studied
Clinical Trials running at Veterans Affairs Medical Center - Madison
Prostate Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Squamous Cell Carcinoma
Cancer
Multiple Myeloma
Obesity
Parkinson's Disease
ALK Gene Rearrangement
Respiratory Infection
High Dose Testosterone
for Prostate Cancer
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Recruiting3 awards Phase 2
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting2 awards Phase 3
Systemic + Local Therapy
for Prostate Cancer
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.
Recruiting1 award Phase 2 & 33 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Veterans Affairs Medical Center - Madison?
Veterans Affairs Medical Center - Madison is a medical facility located in Madison, Wisconsin. This center is recognized for care of Prostate Cancer, Lung Cancer, Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer and other specialties. Veterans Affairs Medical Center - Madison is involved with conducting 115 clinical trials across 162 conditions. There are 10 research doctors associated with this hospital, such as Justine Yang-Bruce, Nasia Safdar, MD PhD, Christopher D Fletcher, MD, and Jessica M. Schuster.